Comparing Go/No-Go Decision-Making Properties Between Single Arm Phase II Trial Designs in Oncology.

The Multilevel approach provides flexibility in interpreting moderate efficacy results. However, the flexibility is accomplished with a lower sample size and corresponding uncertainty in the trial outcome that increases the risk of incorrect drug development decisions.